123 results on '"Platt, James T."'
Search Results
2. Supplementary Table 8 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
3. Supplementary Figure 1 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
4. Data from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
5. Data from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
6. Supplementary Table S5 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
7. Supplementary Table 5 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
8. Supplementary Tables 1-7, 9 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
9. Supplementary Table 3 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
10. Supplementary Figure S1 from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
11. Supplementary Figure 3 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
12. Supplementary Table 1 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
13. Supplementary Table 2 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
14. Data from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
15. Supplementary figure and table legends from Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
16. Supplementary Figure Legends, Table Legends from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
17. Supplementary Figures 1-7 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
18. Supplementary Figure 2 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
19. Supplementary Figure Legends 1-7, Table Legends 1-9 from Genotype-Selective Combination Therapies for Melanoma Identified by High-Throughput Drug Screening
20. Supplementary Table 4 from Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
21. Supplementary Tables 1, 2, 4, and 5 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
22. Supplementary Table 3 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
23. Supplementary Table 6 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
24. Data from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
25. Supplementary Table 7 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
26. Supplementary Methods and Figure Legends from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
27. Supplementary Figures 1 through 9 from Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
28. Supplementary Table S2 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
29. Data from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
30. Supplementary Figures S1-S6 from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
31. Supplementary Table and Figure Legends from PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
32. mTORC1 Activation Blocks BrafV600E-Induced Growth Arrest but Is Insufficient for Melanoma Formation
33. β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas
34. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
35. MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL
36. Salmonella pathogenicity island-2 and anticancer activity in mice
37. Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer
38. Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor
39. Mutational landscape of EGFR-, MYC-, and Kras-driven genetically engineered mouse models of lung adenocarcinoma
40. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
41. The mutational landscape of EGFR-, MYC-, and Kras- driven genetically-engineered mouse models of lung adenocarcinoma
42. SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells
43. Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma
44. The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth ofBRAF-mutant melanoma cells in combination with other signaling pathway inhibitors
45. PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets
46. Abstract 1792: Identification of synergistic drug combinations with the oral HSP90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer
47. Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models
48. Convergent and Divergent Cellular Responses by ErbB4 Isoforms in Mammary Epithelial Cells
49. Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells.
50. Abstract B275: Dovitinib as a single-agent or in combination with other small molecule inhibitors for mutant BRAF melanomas.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.